Autolus is a clinical-stage biopharmaceutical company focusing on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.

Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Autolus is at the forefront of a revolution in cancer treatment. Chimeric Antigen Receptor (CAR) T cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential for cure in some patients. A leader in T-cell programming and manufacturing technology, Autolus are working in partnership with physicians and other healthcare providers to extract immune cells from patients, equip them with a receptor that targets the cancer cell and infuse them back into the patient in order to develop therapies which we believe will offer cancer patients substantial benefits over the existing standard of care.

Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cell product candidates.


Martin Pule

Founder of Autolus

“My ambition is to build a substantial company which can deliver CAR T-cell therapies to patients. Most investors were only interested in developing certain assets with a view to sell them on again, but Syncona was different and shared the long-term goal to create a sustainable business around a portfolio of technologies. They have backed this with a £30m investment and ongoing operational and strategic support”